Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Feb. 17 — The FDA's Science Board will hold a public meeting on March 1 to discuss, among other things, the role that the agency plays in providing appropriate pain treatment while reducing opioid abuse.
The meeting comes as congressional and state leaders have taken actions to address the U.S. opioid abuse epidemic. President Barack Obama also has asked Congress for $1.1 billion in his fiscal year 2017 budget to combat the epidemic, a crisis so severe that it has in part led a handful of senators to block his nominee to run the Food and Drug Administration .
The meeting will be held on March 1 from 8:30 a.m. to 5 p.m. at the FDA's White Oak Campus in Silver Spring, Md. A notice announcing the meeting was published Feb. 17 in the Federal Register (81 Fed. Reg 8,078).
The FDA said the topics for discussion will include:
The agency also said the Science Board will receive a final report from the Centers of Excellence in Regulatory Science and Innovation Program Evaluation Subcommittee.
The Science Board provides advice to the FDA on complex scientific and technical issues important to the agency and its mission, including emerging issues within the scientific community.
Democratic lawmakers, including Sens. Edward Markey (Mass.) and Joe Manchin III (W.Va.), have said they will oppose Robert Califf's nomination to lead the FDA because they think the agency's oversight of opioid painkillers isn't strong enough. The lawmakers said they want the agency to reverse its approval of a pediatric use for OxyContin . Sen. Kelly Ayotte (R-N.H.) recently joined Markey in placing a hold on Califf's nomination because of the agency's approval of OxyContin for kids.
However, the Califf nomination is expected to proceed, with a Feb. 22 cloture vote scheduled.
Several House and Senate bills also have been introduced to deal with the opioid abuse epidemic. Most recently, Manchin introduced a bill (S. 2543) Feb. 11 to amend the FDA's mission statement to say that the agency is “also responsible for protecting the public health by strongly considering the danger of addiction and overdose death associated with prescription opioid medications when approving these medications and when regulating the manufacturing, marketing, and distribution of opioid medications.”
Vermont Gov. Peter Shumlin (D) Feb. 11 also sent a letter to drug manufacturers AstraZeneca and Daiichi Sankyo, asking them to pull an advertisement that first aired during the Super Bowl for Movantik (naloxegol), a drug that treats opioid-induced constipation.
“The irrational exuberance with which opiates are handed out in America is driving the addiction crisis in this country,” Shumlin said. “Now is the time to change that, not attempt to further normalize long-term opiate use by advertising a drug to help people take even more opiates during the most watched sporting event of the year.”
Shumlin asked the companies to immediately pull the advertisement and other advertisements promoting Movantik and “instead use the money to fund opiate and heroin prevention efforts.”
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
The Federal Register notice is at https://www.gpo.gov/fdsys/pkg/FR-2016-02-17/pdf/2016-03152.pdf.
The governor's letter is at http://governor.vermont.gov/node/2623.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)